A Phase 2 interventional study of Ruxolitinib in Primary Myelofibrosis, sponsored by Novartis Pharmaceuticals. Terminated at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-24.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing ruxolitinib in Primary Myelofibrosis — 8 open to participants now, 15 under way, 1 of them phase 3. ruxolitinib · Primary Myelofibrosis.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, this one is the 47th largest by enrollment, is one of 3 that started in 2014, is one of 19 in phase 2, and was the 19th registered.
627 studies on the registry are indexed under Primary Myelofibrosis; 125 are open to participants now.
Browse Primary Myelofibrosis studies →8 of the 50 studies testing ruxolitinib in Primary Myelofibrosis are open now, in 1 country. Recruiting first, the newest first:
University of Utah · Sites in United States
Ages 18+
Fred Hutchinson Cancer Center · Sites in United States
Ages 18–75
M.D. Anderson Cancer Center · Sites in United States
Ages 18+
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
M.D. Anderson Cancer Center · Sites in United States
Ages 18–75
By country, each count listing its studies:
ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →
Of the 101 Primary Myelofibrosis studies recruiting now, 83 (82%) set no upper age limit and 13 (13%) stop at 75 or younger; 10 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 20 · Phase 2 27 · Phase 3 6 · Phase 4 4
First in 2007; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 3 is below the median of 43 across 491 interventional studies indexed under Primary Myelofibrosis.
Median enrollment 45 across the 50 interventional studies. Of the 32 that completed or were terminated, 23 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 50 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,721 studies on the registry; 222 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
24 studies in Primary Myelofibrosis by Novartis: 1 open now, 4 under way, 2 of them phase 3. Of 18 finished, 12 (67%) have results posted.
Among the 24 studies in Primary Myelofibrosis by Novartis, this one is the 19th largest by enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2014, is one of 5 in phase 2, and was the 11th registered.
Novartis’s Primary Myelofibrosis studies by the year they started, since 2001.
6 of the studies testing ruxolitinib in Primary Myelofibrosis that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT06345495M.D. Anderson Cancer CenterHigh Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly | 2027-01-01 |
| NCT05371964Geron CorporationA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis | 2027-02 |
| NCT03069326Memorial Sloan Kettering Cancer CenterA Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis | 2027-02 |
Add all 6 to your calendar (.ics) → With an account.
Among the 50 studies testing ruxolitinib in Primary Myelofibrosis, from their registry updates:
Among Novartis’s 24 in Primary Myelofibrosis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The aim of the study is to assess the efficacy and safety of restarting ruxolitinib after treatment interruption due to loss of response and/or adverse events.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All participants received ruxolitinib.
Drug: Ruxolitinib
Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to \<200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
Proportion of Patients Achieving ≥20% Reduction From Baseline in Spleen Volume
Time frame: Week 24
Proportion of Patients Achieving ≥35% Reduction From Baseline in Spleen Volume
Time frame: Week 24
Proportion of Patients Achieving ≥25% and ≥50% Reduction, Respectively From Baseline, in Spleen Length
Time frame: Week 24
Change From Baseline in Spleen Length and Spleen Volume
Time frame: Baseline, Week 24
Proportion of Patients Achieving ≥25% and ≥50% Reduction, Respectively, From Baseline in Total Symptom Score (MPN-SAF TSS)
Time frame: Week 24
Change From Baseline in MPN-SAF TSS Score
Time frame: Baseline, Week 24
Patient Global Impression of Change (PGIC) Score
Time frame: Week 1, Week 24
Change From Baseline in European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 and EuroQol (EQ)-5D-5L Scores
Time frame: Baseline, Day 1, Week 8, Week 12, Week 16, Week 24
| Milestone | Ruxolitinib |
|---|---|
| Started | 3 |
| Completed | 0 |
| Not completed | 3 |
| Withdrew: Study terminated by sponsor | 2 |
| Withdrew: Adverse event | 1 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
No measurements were reported for this outcome.
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ruxolitinib | — | 2/3 (66.7%) | 2/3 (66.7%) |
| Event | Ruxolitinib |
|---|---|
| CONSTIPATIONGastrointestinal disorders | 1/3 |
| CYTOKINE RELEASE SYNDROMEImmune system disorders | 1/3 |
| LISTERIOSISInfections and infestations | 1/3 |
| RENAL FAILURERenal and urinary disorders | 1/3 |
| Event | Ruxolitinib |
|---|---|
| ANAEMIABlood and lymphatic system disorders | 1/3 |
| ANAL HAEMORRHAGEGastrointestinal disorders | 1/3 |
| ASCITESGastrointestinal disorders | 1/3 |
| CONSTIPATIONGastrointestinal disorders | 1/3 |
| DIARRHOEAGastrointestinal disorders | 1/3 |
| VARICES OESOPHAGEALGastrointestinal disorders | 1/3 |
| PORTAL VEIN THROMBOSISHepatobiliary disorders | 1/3 |
| CYSTITISInfections and infestations | 1/3 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 1/3 |
| ASPARTATE AMINOTRANSFERASE INCREASEDInvestigations | 1/3 |
| Age, Continuous(Years) | Ruxolitinib |
|---|---|
| Mean | 68.00 ± 9.165 |
| Sex: Female, Male(Participants) | Ruxolitinib |
|---|---|
| Female | 2 |
| Male | 1 |
The record gives a start of Sep 2014, a primary completion of Feb 2015 and a completion of Feb 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Feb 2016, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ruxolitinib